Goldman Sachs maintains Conviction Buy on Biogen (NASDAQ: BIIB) price target of $376.00.Analyst Terrance Flynn believes investors should buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE